Holen Sie sich die Stockscreener-App
0.4417
6.91%
-0.0328
Handel nachbörslich:
.44
-0.0017
-0.38%
Schlusskurs vom Vortag:
$0.4745
Offen:
$0.47
24-Stunden-Volumen:
159.42K
Relative Volume:
1.03
Marktkapitalisierung:
$17.99M
Einnahmen:
$7.88M
Nettoeinkommen (Verlust:
$-69.20M
KGV:
-0.2414
EPS:
-1.83
Netto-Cashflow:
$-69.73M
1W Leistung:
-9.21%
1M Leistung:
-13.39%
6M Leistung:
-35.02%
1J Leistung:
-63.50%
1-Tages-Spanne:
$0.4411
$0.4701
1-Wochen-Bereich:
$0.4411
$0.489
52-Wochen-Spanne:
$0.4411
$1.56
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Firmenname
Bolt Biotherapeutics Inc
Sektor
Branche
Telefon
650-665-9295
Adresse
900 CHESAPEAKE DRIVE, REDWOOD CITY
Vergleichen Sie BOLT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
0.4417 | 17.99M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | Eingeleitet | Guggenheim | Buy |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Bolt Biotherapeutics Inc Aktie (BOLT) Neueste Nachrichten
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire
BOLT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Bolt Biotherapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Bolt Biotherapeutics stock hits 52-week low at $0.46 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.46 - Investing.com India
Bolt Biotherapeutics to Participate in Upcoming March Conferences - The Manila Times
Can Bolt Biotherapeutics' March Conference Appearances Signal New Clinical Developments? - StockTitan
Long Term Investors in Bolt Biotherapeutics, Inc. (NASDAQ: - openPR
Bolt Biotherapeutics, Inc. (BOLT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. - The Manila Times
Major Cancer Treatment Breakthrough: Bolt and Toray Target Caprin-1 in Solid Tumors - StockTitan
BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Breast Cancer FDA Approvals, Pipeline Insights, Clinical Trials, Emerging Drugs and Companies | DelveInsight - The Globe and Mail
BOLT Stock Earnings: Bolt Biotherapeutics Misses EPS, Beats Revenue for Q2 2024 - MSN
Bolt Biotherapeutics shifts to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics shifts to Nasdaq Capital Market - Investing.com India
Bolt Biotherapeutics, Inc. Announces Board and Committee Changes, Effective December 31, 2024 - Marketscreener.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Purchased by Fmr LLC - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Bolt Biotherapeutics stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.53 - Investing.com India
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesBOLT - The Eastern Progress Online
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully - Simply Wall St
Bolt Biotherapeutics (BOLT) Stock Surges Amid Biotech Sector Mov - GuruFocus.com
Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B - Endpoints News
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Bolt Biotherapeutics stock hits 52-week low at $0.54 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.54 - Investing.com
HC Wainwright Issues Pessimistic Forecast for BOLT Earnings - Defense World
Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look - TipRanks
Bolt Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot - Houston Chronicle
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation - Yahoo Finance
Finanzdaten der Bolt Biotherapeutics Inc-Aktie (BOLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):